相似文献
1
[From the first french Telethon to the rare diseases act: the role of AFM].
Arch Pediatr. 2010 Jun;17(6):699. doi: 10.1016/S0929-693X(10)70066-X.
2
[Rare diseases health plan: outcome and expectations].
Arch Pediatr. 2010 Jun;17(6):700-1. doi: 10.1016/S0929-693X(10)70067-1.
3
[The telethon and the promises not kept by gene therapy].
Rev Med Suisse. 2013 Dec 18;9(411):2402-3.
4
[Telethon--a bioethical crystallization].
Rev Med Suisse. 2007 Nov 28;3(135):2756.
5
[Neuromuscular diseases are many but rare].
Lakartidningen. 2013;110(15):752-3.
6
[The French Myology Association Telethon--investments in innovative projects].
Med Sci (Paris). 2015 Nov;31 Spec No 3:50. doi: 10.1051/medsci/201531s315. Epub 2015 Nov 6.
7
[Optimising treatment for people with rare diseases].
Ugeskr Laeger. 2006 Apr 10;168(15):1547-50.
8
Advocates to bring rare disease philanthropy under one umbrella.
Nat Med. 2010 Aug;16(8):837. doi: 10.1038/nm0810-837b.
9
The role of patient advocacy organisations in neuromuscular disease R&D--The case of the Dutch neuromuscular disease association VSN.
Neuromuscul Disord. 2010 Feb;20(2):148-51. doi: 10.1016/j.nmd.2009.10.012.
10
French institute prepares for gene-therapy push.
Nature. 2012 Jan 25;481(7382):423-4. doi: 10.1038/481423a.
Zotero 插件